Department of Gastroenterology, Hepatology, and Endoscopy.
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute.
J Clin Gastroenterol. 2019 Nov/Dec;53(10):e424-e430. doi: 10.1097/MCG.0000000000001122.
Hepatitis B virus (HBV) screening during pregnancy is standard of care to prevent vertical transmission to infants, yet the mothers themselves may not receive appropriate follow-up.
Using a national database, we sought to determine rates of maternal peripartum follow-up with a HBV specialist and identify factors associated with a lack of follow-up.
We identified women who delivered in 2000 to 2012 and were diagnosed with HBV according to International Classification of Diseases-9 codes using a national database (Optum) derived from commercial insurance claims with ∼46 million members ages 0 to 64 in all 50 states. Our primary outcome was follow-up during or after pregnancy with a HBV specialist (gastroenterology/infectious diseases).
The prevalence of HBV was 0.27% (2558/959,747 pregnancies), and median follow-up was 45 months. Only 21% of women had peripartum HBV specialist follow-up. On multivariable regression, predictors of peripartum follow-up at 1-year included younger age [odds ratio (OR), 0.97/y; 95% confidence interval (CI), 0.94, 0.99], Asian race/ethnicity (OR, 1.56 vs. white; 95% CI, 1.13, 2.17), and residing in the Northeast (OR, 1.70; 95% CI, 1.09, 2.66) and Midwest (OR, 1.73; 95% CI, 1.07, 2.81) versus West. Predictors of testing for HBV DNA and alanine aminotransferase at 1 year included Asian race (OR, 1.72; 95% CI, 1.23, 2.41), a primary care physician visit within 2 years of delivery (OR, 1.63; 95% CI, 1.19, 2.22), and peripartum HBV specialist follow-up within 1 year (OR, 15.68; 95% CI, 11.38, 21.60).
Maternal HBV specialist follow-up rates were extremely low in this large, diverse cohort representing all United States regions. Referral to a HBV specialist was the strongest predictor of appropriate postpartum HBV laboratory testing. Follow-up rates may be even lower in uninsured populations.
乙型肝炎病毒 (HBV) 筛查在孕期是预防母婴垂直传播的标准措施,但母亲本身可能无法接受适当的后续治疗。
我们利用国家数据库,旨在确定母婴围产期与乙型肝炎病毒专家随访的比率,并确定与随访缺失相关的因素。
我们使用全国数据库(来自商业保险索赔的 Optum,覆盖 50 个州的 4600 万 0 至 64 岁的成员),根据国际疾病分类第 9 版 (ICD-9) 代码,确定了 2000 年至 2012 年分娩并被诊断为 HBV 的女性。我们的主要结局是在孕期或产后与乙型肝炎病毒专家(胃肠病学/传染病学)进行随访。
HBV 的患病率为 0.27%(2558/959747 例妊娠),中位随访时间为 45 个月。仅有 21%的女性在围产期接受了乙型肝炎病毒专家随访。多变量回归分析显示,1 年内进行围产期随访的预测因素包括年龄较小[比值比 (OR),0.97/年;95%置信区间 (CI),0.94,0.99]、亚裔/族裔(OR,1.56 比白人;95%CI,1.13,2.17)、居住在东北部(OR,1.70;95%CI,1.09,2.66)和中西部(OR,1.73;95%CI,1.07,2.81)而不是西部。1 年内进行乙型肝炎病毒 DNA 和丙氨酸氨基转移酶检测的预测因素包括亚裔种族(OR,1.72;95%CI,1.23,2.41)、分娩后 2 年内有初级保健医生就诊(OR,1.63;95%CI,1.19,2.22)和 1 年内有围产期乙型肝炎病毒专家随访(OR,15.68;95%CI,11.38,21.60)。
在代表美国所有地区的大型多样化队列中,母婴乙型肝炎病毒专家随访率极低。转诊给乙型肝炎病毒专家是进行适当产后乙型肝炎病毒实验室检测的最强预测因素。在没有保险的人群中,随访率可能更低。